DrugPatentWatch Database Preview
Drugs in Development Information for SM04690
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for SM04690?
SM04690 is an investigational drug.
There have been 8 clinical trials for SM04690.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2020.
The most common disease conditions in clinical trials are Osteoarthritis, Osteoarthritis, Knee, and Spinal Diseases. The leading clinical trial sponsors are Samumed LLC and [disabled in preview].
There are seven US patents protecting this investigational drug and fifty-eight international patents.
Summary for SM04690
| US Patents | 7 |
| International Patents | 58 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2020-05-01) |
| Vendors | 13 |
Recent Clinical Trials for SM04690
| Title | Sponsor | Phase |
|---|---|---|
| A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteaoarthritis | Samumed LLC | Phase 3 |
| A Phase 3 Study Utilizing Patient-Reported and Radiograhic Outcomes and Evaluating the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteaoarthritis | Samumed LLC | Phase 3 |
| A Study Utilizing Imaging Techniques and Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis | Samumed LLC | Phase 2 |
Clinical Trial Summary for SM04690
Top disease conditions for SM04690
Top clinical trial sponsors for SM04690
US Patents for SM04690
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SM04690 | Start Trial | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | Samumed, LLC (San Diego, CA) | Start Trial |
| SM04690 | Start Trial | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | Samumed, LLC (San Diego, CA) | Start Trial |
| SM04690 | Start Trial | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | Samumed, LLC (San Diego, CA) | Start Trial |
| SM04690 | Start Trial | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | Samumed, LLC (San Diego, CA) | Start Trial |
| SM04690 | Start Trial | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | Samumed, LLC (San Diego, CA) | Start Trial |
| SM04690 | Start Trial | Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof | Samumed, LLC (San Diego, CA) | Start Trial |
| SM04690 | Start Trial | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof | Samumed, LLC (San Diego, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SM04690
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SM04690 | Australia | 2017274350 | 2036-06-01 | Start Trial |
| SM04690 | Brazil | 112018074725 | 2036-06-01 | Start Trial |
| SM04690 | Canada | 3026076 | 2036-06-01 | Start Trial |
| SM04690 | Chile | 2018003423 | 2036-06-01 | Start Trial |
| SM04690 | China | 109476660 | 2036-06-01 | Start Trial |
| SM04690 | European Patent Office | 3464285 | 2036-06-01 | Start Trial |
| SM04690 | Israel | 263362 | 2036-06-01 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
